Overview

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Status:
RECRUITING

Trial end date:
2033-02-26

Target enrollment:

Participant gender:

Summary

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

remibrutinib